[AI Generated Pharma News]

• Pfizer has acquired the Chinese commercialization rights for Sciwind’s GLP-1 drug, ecnoglutide, in a deal valued at up to $495 million to target the region's growing metabolic disorder market.

• GSK is expanding its respiratory and cardiovascular pipeline through a $950 million acquisition of 35Pharma, gaining access to a promising activin signaling inhibitor for pulmonary hypertension.

• Novo Nordisk has entered a potential $2.1 billion partnership with Vivtex to leverage proprietary technology for developing oral formulations of biologic drugs like GLP-1 therapies.